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Mycoplasma pneumoniae is the causative agent of primary atypical pneumonia in humans. Adherence of M.
pneumoniae to host cells requires several adhesin proteins, such as P1, P30, and P116. A major limitation in
developing a specific diagnostic test for M. pneumoniae is the inability to express adhesin proteins in heter-
ologous expression systems due to unusual usage of the UGA stop codon, leading to premature termination of
these proteins in Escherichia coli. In the present study, we successfully expressed the C-terminal (P1-C1) and
N-terminal (P1-N1) regions of the P1 protein in E. coli. On screening these recombinant proteins with sera
from M. pneumoniae-infected patients, only the P1-C1 protein was found to be immunogenic. This protein can
be used as an antigen for immunodiagnosis of M. pneumoniae infection, as well as in adherence inhibition
studies to understand the pathophysiology of the disease.
Mycoplasma pneumoniae is the causative agent of atypical
pneumonia and is also responsible for other respiratory tract
infections such as tracheobronchitis, bronchiolitis, croup, and
less severe upper respiratory tract infections in older children
and young adults (3, 14). It has been estimated that between 10
and 20% of X-ray-proven pneumonia cases that occur in the
endemic period and that up to 50% of all cases that occur in
the epidemic period are caused by M. pneumoniae (7, 23).
Adherence of M. pneumoniae to the human host respiratory
epithelium is a prerequisite for colonization of the respiratory
epithelium and subsequent induction of disease (12, 14).
Cytadherence is mediated by a specialized tip-like attachment
organelle found in M. pneumoniae (8, 21). It requires a com-
plex interaction of several M. pneumoniae proteins present on
the attachment organelle, including the major surface adhesins
P1 (170 kDa), P30 (30 kDa), and P116 and proteins HMW1 to
HMW5, as well as proteins A, B and C (1, 10, 14, 24, 29, 30).
These proteins cooperate structurally and functionally so that
M. pneumoniae major surface adhesins display polar clustering
at the organelle tip assisted by HMW proteins. The major
proteins P1 and P30 appear to be directly involved in receptor
binding (5, 13, 21). The HMW proteins and proteins A, B, and
C are accessory proteins since they are not adhesins but are
required for proper functioning. The native adhesins P1 and
P30 are also known to be strongly immunogenic in humans and
experimental animals infected with M. pneumoniae.
The true incidence ofM. pneumoniae associated infection is not
clear because of the nonavailability of rapid and specific diagnos-
tic tests. Being a fastidious organism, M. pneumoniae grows slowly
and poorly. The standard methods for the diagnosis of M. pneu-
moniae are culture, serology, and PCR. Since M. pneumoniae can
be difficult to isolate (11), laboratory diagnosis is based on sero-
logical tests, such as complement fixation and enzyme-linked im-
munosorbent assays (ELISAs) (31). PCR has also been used for
its detection (6, 34). The complement fixation test has limited
value and produces inconclusive results because it also measures
antibodies from previous infections (26). The glycolipid antigen,
which is not M. pneumoniae specific, cross-reacts with antigens of
other microorganism and body tissues (3). Since serology is often
used for the diagnosis of M. pneumoniae infections (15), it is
important to identify specific antigen(s) that can distinguish be-
tween previous and current infections. Recently, the P1 protein
has been used as an antigen for the immunodiagnosis of M.
pneumoniae infection (19). However, technical difficulties in pro-
tein purification and its large-scale expression limits its diagnostic
use. The P1 gene contains an open reading frame of 4,881 nucle-
otides coding for a protein of 1,627 amino acids with a calculated
molecular weight of 176,888 and contains 21 UGA codons that
code for tryptophan (29). The presence of these UGA codons
makes it difficult to express the P1 protein in Escherichia coli as
UGA codes for a stop codon. A number of attempts have been
made to express this protein by using different expression systems
(9, 27, 33). To circumvent these problems, we decided to express
two different regions of the P1 protein in E. coli. This includes the
N-terminal (P1-N1) and a C-terminal (P1-C1) region, which have
been suggested to be immunodominant and to act as adhesins
(17). The UGA codons in these fragments were modified to
UGG, the genes were cloned and expressed in E. coli and immu-
nological characterization of both the proteins were undertaken.
MATERIALS AND METHODS
Organisms and growth conditions. The lyophilized ampoule of M. pneumoniae
standard strain (FH lieu; National Collection of Type Cultures, London, United
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Kingdom) was reconstituted in Edward Hayflick medium containing PPLO basal
broth that was supplemented with 1% glucose (Difco) as the carbon source and
0.0002% phenol red as the indicator. Tissue culture flasks (Nunc, Roskilde,
Denmark) were incubated at 37°C aerobically and inspected daily. An exponen-
tial growth phase was indicated by a change in color of the medium from red to
orange. Cells were harvested at this stage, washed in phosphate-buffered saline
(PBS), and centrifuged, and the pellet was stored at 70°C. The organism was
confirmed by subculturing 0.2 ml of the broth culture on PPLO agar plates
(Borosil). Plates were incubated at 37°C in 5% CO2 in a candle jar and were
examined at 3 day intervals. Suspected colonies were confirmed by Dienes
staining and by growth inhibition test with M. pneumoniae polyclonal antisera
(National Collection of Type Cultures).
PCR amplification of N-terminal (P1-N1) and C-terminal fragments (P1-C1)
of the P1 gene. To circumvent the translational barrier of UGA codon, we
searched the P1 gene-encoded protein for functional domains involved in cytad-
herence and immunodominant regions. Based on published literature, we de-
cided to express two of these regions, the N-terminal region [P1-N1] (18) and the
C-terminal region [P1-C1] (4), encompassing amino acid residues 60 to 180 and
1160 to 1521, respectively.
Genomic DNA extracted from the standard strain of M. pneumoniae (FH lieu)
was used as a template for amplification of N-terminal and C-terminal regions of
the P1 gene. DNA was extracted according to the method of Stauffer et al. (28)
and then subjected to PCR amplification.
For PCR amplification of the P1-N1 region, we used the following primer sets
(Biobasic, Inc.). For the P1-N1 region the forward (P-1c) 5-AGA TCT GAA
TTC AAT GCC ATC AAC CCG CGC TTA ACC CCG TGG ACG TAT CG-3
and reverse (P-1d) 5-CCC AAG CTT GAC CTC GTT CCA CTG TTG GGG
TGC AGC CCC-3 primers were used, and for the P1-C1 region the forward
(P-1e) 5-AGA TCT GAA TTC GCG GCC TTT CGT GGC AGT TGG GTC-3
and reverse (P-If) 5-CAT TGG CTG CAG ATC AGG CCA CTG GTT AAA
CGG ACT AAA CAA-3 primers were used. These primers were designed so
that the UGA codon was changed to UGG for an E. coli expression system.
PCR was performed in a total of 100 l of reaction mixture containing 1
PCR buffer (100 mM Tris-HCl [pH 9.0], 500 mM KCl,15 mM MgCl2, and 0.1%
gelatin), 200 M deoxynucleoside triphosphates, 50 pmol of each primer, 1 U of
Taq polymerase (3 U/l; Bangalore Genei, Bangalore, India), and template
DNA (100 ng). Amplification was carried out by denaturation at 94°C for 1 min,
annealing at 62°C for 1 min, and extension at 72°C for 3 min for 35 cycles. PCR
products were analyzed on 1.5% agarose gel, and the amplified fragments of
1,085 and 362 bp were purified by using gel extraction kit (Qiagen).
Cloning and expression of P1-N1 and P1-C1 regions of P1 gene. PCR ampli-
fied fragments were first ligated into the pGEMT vector (Promega). The ligation
mixtures were used to transform competent DH5 E. coli cells. Transformants
were selected on Luria-Bertani (LB) agar containing ampicillin (100 g/ml).
Individual colonies were picked up and grown overnight in 5 ml of LB broth
containing ampicillin (100 g/ml). Plasmid DNA was isolated from overnight
cultures by using Miniprep plasmid extraction kit (Qiagen) and digested with
EcoRI to ensure the presence of the inserts. These inserts were then sequenced
to rule out any mutations.
For the expression, the inserts were released from pGEMT clones by restric-
tion digestion with BglII and PstI for the 1,085-bp P1-C1 insert and with BglII
and HindIII for the 362-bp P1-N1 insert. After gel purifications, the inserts were
ligated into the expression vector pQE-30 (Qiagen) digested at corresponding
sites. Ligation mixtures were used to transform M15 cells, and transformants
were selected on kanamycin (25 g/ml) and ampicillin (100 g/ml) plates. Plas-
mid DNA was extracted from overnight cultures and subjected to restriction
digestion to check the inserts.
M15 cells containing the recombinant plasmids were cultivated in 5 ml of LB
broth (containing ampicillin and kanamycin as described above) at 37°C with
shaking until the optical density (OD) reached 0.5 to 0.6. Protein expression was
induced by 1 mM IPTG (isopropyl--D-thiogalactopyranoside; Sigma). After 3 h
of shaking incubation at 37°C, bacteria were pelleted by centrifugation and
further subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) to check the expression of recombinant proteins (25).
SDS-PAGE and Western blotting:. For SDS-PAGE analysis, crude E. coli
lysates expressing the recombinant P1 fragments (50 g) were dissolved in 30 l
of SDS sample buffer (62.5 mM Tris-HCl [pH 6.8], 10% glycerol, 2.3% [wt/vol]
SDS, 5% [vol/vol] -mercaptoethanol, and 0.05% [wt/vol] bromophenol blue)
and boiled for 2 min. The proteins were separated by SDS–10% PAGE and
subsequently stained with Coomassie brilliant blue R-250. To ascertain the
expression of the recombinant proteins, Western blotting was performed for E.
coli cell extracts by using Penta-His monoclonal antibodies (Qiagen). Purified
recombinant protein P1-C1 was also studied for its reactivity with anti-M. pneu-
moniae infected pooled human sera and individual sera (collected from patients
with community-acquired pneumonia who tested positive for immunoglobulin G
[IgG] antibodies to M. pneumoniae [Serion Classic ELISA kit; Serion GmbH,
Wurzburg, Germany]). For immunoblotting, E. coli extracts expressing recom-
binant P1-C1/P1-N1 and purified recombinant P1-C1 protein were separated by
SDS-PAGE, and proteins were transferred to nitrocellulose membrane by stan-
dard procedures (32). The membranes were blocked with 5% casein at room
temperature for 1 h. After being washed with PBS-Tween 20, the blots were
incubated with Penta-His monoclonal antibodies at a dilution of (1:2,000) or
anti-M. pneumoniae antibody-positive pooled human sera (n  20; the same
individual patients sera were mixed equally to make pooled sera) at a dilution of
1:100 in two separate experiments. The dilution used for the pooled sera, as well
as for the individual sera, was the same. The negative control was negative
individual sera (tested negative by commercial kit), and it was also diluted to the
same extent.
The blots were reacted with peroxidase-conjugated anti-mouse IgG (1:1,000
dilution) or anti-human IgG (1:1,000 dilution), respectively. After being washed,
the final enzyme reaction was developed with 4-chloro-1-naphthol and H2O2.
Purification of recombinant P1-C1 protein:. Once we ascertained that the
expressed proteins were of M. pneumoniae origin, we purified recombinant pro-
tein P1-C1 by using an Ni-nitrilotriacetic acid (NTA) column (Qiagen). For
large-scale production of P1-C1 protein, 100 ml of culture of E. coli cells ex-
pressing P1-C1 were grown and induced with 1 mM IPTG. After the induction,
the bacterial pellet was obtained by centrifugation at 5,000  g for 30 min at 4°C
and then resuspended in 10 ml of sonication buffer (50 mM Na2HPO4 [pH 7.0],
120 mM NaCl, 1 mM phenylmethylsulfonyl fluoride). Cells were sonicated with
a 5-min pulse at 2-min intervals. The supernatant was incubated at 4°C with
Ni-NTA agarose resin (Qiagen) with constant shaking. After 1 h, the resin was
packed to a column and extensively washed with the sonication buffer, followed
by wash buffer (57 mM Na2HPO4 [pH 6.0], 128 mM NaCl, and 10% glycerol).
Bound proteins were eluted with Tris-HCl (pH 8.0) containing 0.25 M imidazole
(Sigma). Fractions containing the recombinant protein with a high degree of
purity were pooled and extensively dialyzed against PBS, and the protein con-
centration was determined by Lowry method (22).
Comparative ELISA with purified P1-C1 epitope and commercial IgG assay.
Serum samples were collected from adult patients with community-acquired
pneumonia and then screened for anti-M. pneumoniae IgG antibodies by using
the commercial Serion Classic ELISA kit, which has a sensitivity of 100% and a
specificity of 90% according to the manufacturer’s instructions. A total of 33
IgG-positive sera and 32 IgG-negative sera were included in the present study.
Antibody responses to recombinant protein P1-C1 were evaluated by ELISA.
Flat-bottom 96-well Immulon plates (Dynatech) were coated with 100 ng of the
recombinant protein per well in 0.06 M carbonate-bicarbonate buffer (pH 9.6)
and then incubated overnight at 4°C and a further 1 h at 37°C. The uncovered
reactive sites were blocked with 2% skimmed milk in PBS at 37°C for 2 h. The
antigen-coated wells were incubated sequentially for 1 h with 1:100-diluted test
sera and a 1:10,000 dilution of peroxidase-labeled goat anti-human IgG. In
between these incubations, the plates were washed thrice with PBS containing a
0.05% Tween 20. The enzyme reaction was developed by the addition of 1 mg of
ortho-phenylenediamine (Sigma)/ml diluted in phosphate-citrate buffer (pH 5.0)
containing 0.03% (vol/vol) hydrogen peroxide. The enzymatic reaction was
stopped with 8 N H2SO4, and the OD at 492 nm (OD492) of the reaction product
in the wells was recorded with a Bio-Tek microplate reader. The sample was
considered positive if the OD492 was 	0.5.
RESULTS
Generation of recombinant fragments of P1 protein and
their characterization. Fragments of the P1 gene, i.e., P1-N1
and P1-C1 (Fig. 1), were amplified by PCR and then expressed
in E. coli M15 cells by using pQE-30 vector. Both of the
recombinant protein fragments were successfully expressed in
E. coli, and the expression level of P1-C1 was found to be quite
high. Figure 2A shows the expression levels of these proteins as
detected by SDS-PAGE. The apparent molecular masses were
13.9 kDa for P1-N1 and 
39.7 kDa for P1-C1. Upon immu-
noblotting, both of the recombinant proteins in E. coli cell
lysates reacted nicely with Penta-His monoclonal antibody
(Fig. 2B). However, with pooled patient sera only P1-C1 frag-
ment was recognized (Fig. 2C). Recombinant purified P1-C1
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reacted nicely with individual and pooled positive sera and also
with anti-histidine antibodies (see Fig. 4).
Purification of recombinant P1-C1 fragment. Purification of
P1-C1 was initiated by lysis of the E. coli pellet and then by
analysis of protein in the soluble fraction as well as in the E.
coli pellet. The protein was found to be expressed in the sol-
uble fraction. This was purified by Ni-NTA affinity chromatog-
raphy to apparent homogeneity (Fig. 3). Fractions that showed
the single P1-C1 band were pooled, dialyzed, and used for
Western blot and comparative ELISA analyses. On immuno-
blotting, the purified recombinant P1-C1 protein reacted well
with anti-histidine antibodies and with individual and pooled
patient sera. The protein did not show any reactivity with
negative human sera (Fig. 4).
Comparative ELISA analysis. Comparative evaluation of
the reactivity of the patient sera with P1-C1, as well as with a
Serion Classic ELISA kit, was carried out. In our ELISA ex-
periment with purified P1-C1 protein as an antigen, of the 33
FIG. 1. Schematic diagram showing P1 gene sequence and location
of the P1-C1 and P1-N1 regions.
FIG. 2. (A) SDS-PAGE showing the expression of P1-C1 and P1-N1 proteins in E. coli extracts. Lanes: 1, standard protein marker; 2,
uninduced P1-C1; 3, induced P1-C1; 4, uninduced P1-N1; 5, induced P1-N1. (B and C) Western blot analysis of E. coli extracts showing the
expression of P1-C1 and P1-N1 proteins with anti-histidine antibody (B) and with pooled patient sera (C). Lanes: 1, prestained protein marker;
2, induced P1-N1 (
13.9 kDa); 3, induced P1-C1 (
39.7 kDa).
FIG. 3. SDS-PAGE showing purification of P1-C1 protein on Ni-
NTA column. Lanes: 1, standard protein marker; 2, 3, and 4, 0.25 mM
imidazole elutions; 5, flowthrough; 6, induced E. coli cell pellet sample
expressing P1-C1.
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positive sera selected based on the reactivity with Serion-
Virion kit, 24 reacted with P1-C1 (Fig. 5A). A total of 32
patients sera who showed no reactivity when tested with the
Serion-Virion ELISA kit also did not react with the P1-C1
fragment (Fig. 5B).
Statistical analysis. Comparative statistical analysis of
P1-C1 ELISA, taking the Serion-Virion ELISA as the stan-
dard, has been done by applying the diagnostic test. For P1-C1,
the cutoff value was taken as 0.5 absorbance. At 0.5 absor-
bance, the cutoff points for the sensitivity and specificity of
P1-C1 were determined to be 72.7% (24 of 33) and 100% (32
of 32), respectively.
DISCUSSION
The major limitation of developing a specific diagnostic test
for M. pneumoniae is the inability to express the specific pro-
teins of M. pneumoniae in heterologous expression systems due
to the unusual codon usage of UGA for stop codon. Although
in other systems this is a stop codon, in M. pneumoniae it codes
for tryptophan. We were interested in identifying the antigenic
sites of the P1 gene, which may serve as candidate antigens in
developing a diagnostic assay. In the present study, a simple
cloning strategy was adopted to express stretches of the P1
gene that are known to be immunogenic and are also involved
in cytadherence.
Toward this end, we expressed two domains of P1 gene, one
in the N-terminal region and another in the C-terminal region.
Both the fragments were expressed in E. coli by using the
pQE-30 expression system. In our study, the C-terminal region
was found to be immunogenic since it showed strong reactivity
on immunoblotting with M. pneumoniae IgG antibody-positive
patient sera, whereas the region corresponding to N-terminal
position showed no reactivity with these sera. We purified the
C-terminal domain of the P1 adhesin by using an Ni-NTA
affinity column and then used this purified protein for compar-
ative ELISA analysis with the Serion Classic ELISA kit. This
kit has been reported to be 100% sensitive and 90% specific as
described in the manufacturer’s instructions (20) and was
found to be useful in our previous study (2) for the diagnosis of
M. pneumoniae infection.
During the course of our study, we came across a report by
Svenstrup et al. (30), who expressed three different regions of
P1 protein spanning N-terminal, middle, and C-terminal parts
in an E. coli expression system. One of the regions, P116,
overlapped with the fragment P1-C1 expressed in the present
study. Svenstrup et al. raised monoclonal antibodies to these
fragments and showed that anti-P116 antibody blocked attach-
ment of M. pneumoniae to the respiratory epithelial cells. How-
ever, they did not check the immunoreactivity of this protein
against patient sera. Interestingly, the immunodominant
epitope found in the C-terminal part of P1 gene in our study
was also shown to be immunodominant as well as cytadherent
by Dallo et al. (4). This author detected a region of P1 gene
spanning 4067 to 4185 bp while screening a gt11 library with
patient sera.
A recombinant protein corresponding to the N-terminal re-
gion of P1 gene in this study codes for a P1 protein that has
been shown to be immunogenic by Jacobs et al. (18) by using
a chemically synthesized peptide. However, in our study this
region was found to be nonreactive with patient sera. The
reason for the nonimmunogenicity of the P1-N1 portion may
be that immunoreactive epitopes may be hidden in the ex-
pressed P1-N1 fragment or it may be due to the biological
mimicry between P1 epitopes and mammalian antigens, as
suggested in another study (16).
In conclusion, the results from the present study indicate
that the C-terminal region of the P1 protein is an important
antigen and can be used along with two other adhesin mole-
cules, P30 and P116, for the development of a sensitive assay
FIG. 4. Immunoblot analysis of purified P1-C1 protein with indi-
vidual and pooled IgG. Results with positive patient sera and with
anti-histidine antibodies are shown. Lanes 2, 19, 27, 17, and 25 repre-
sent positive individual sera. Lane 16 represents a negative control
(negative individual sera, tested negative by commercial kit). PS,
P1-C1 reacted with positive pooled sera; M, standard protein marker;
PH, P1-C1 reacted with anti-histidine antibodies.
FIG. 5. Comparative ELISA analysis with recombinant P1-C1 and
Serion-Virion test with 65 patients. (A) Positive patient sera; (B) neg-
ative patient sera.
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for the diagnosis of M. pneumoniae infection. The use of this
protein to study cytadherence may also provide insight into the
pathophysiology of this disease.
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